← Back to directory
O
OrbiMed
New York City, NY, United StatesWebsite ↗
OrbiMed is a leading global investment firm dedicated exclusively to the healthcare sector, investing in companies engaged in biopharmaceutical products, medical technologies, medical devices, diagnostics, digital health, and healthcare services. The firm employs a multi-stage, multi-strategy approach, supporting companies from early-stage ventures to large multinational corporations through public equity, private equity, and private credit/royalty investments.
Last raised
Aug 2025
10 mo ago
Latest fund size
$1.9B
OrbiMed Royalty and Credit Opportunities Fund V
AUM
$20B
estimated
Funds raised
Capital this firm has raised, newest first
OrbiMed Royalty and Credit Opportunities Fund V
Aug 2025
$1.9B
OrbiMed Private Investments IX
Oct 2023
—
OrbiMed Asia Partners V
Oct 2023
—
OrbiMed Royalty & Credit Opportunities IV
Oct 2023
—
OrbiMed Private Investments VIII
Mar 2021
$1.5B
OrbiMed Asia Partners IV
Mar 2021
$800M
OrbiMed Royalty & Credit Opportunities III
Mar 2021
$1.2B
Recent investments
Companies this firm has funded, newest first
| Company | Round | Amount | Date | Source |
|---|---|---|---|---|
| TruNativ | — | — | Jun 2026 | |
| Congruence Therapeutics | — | $39.5M | Mar 2026 | |
| ThrombolexLead | Series A | $50M | Mar 2026 | |
| QL Biopharma | — | $72.8M | Mar 2026 | |
| Angitia Biopharmaceuticals | — | $130M | Feb 2026 | |
| Mendra | Series A | $82M | Jan 2026 | |
| Mirador Therapeutics | Series B | $250M | Jan 2026 | |
| BlossomHill Therapeutics | Series B | $84M | Dec 2025 |
Sources
Where this data came from